临床肝胆病杂志2011，Vol.27Issue(12)：1285-1287,1300,4.
干扰素α-2b治疗HBeAg阳性慢性乙型肝炎患者CD4+/CD8+T细胞活化分子CD69和HLA-DR的表达
Study on the expression of HLA-DR/CD69 on CD4 +/CD8 + T cells in the treatment of HBeAg-positive chronic hepatitis B with interferon alfa-2b
摘要
Abstract
Objective To study the efficacy prediction and the activation of CD4 + /CD8 + T cells in the treatment of HBeAg - positive chronic hepatitis B with interferon alfa -2b. Methods 32 patients were given interferon alfa -2b 5 MU every other day for 24 weeks. PBH|C were isolated from fresh peripheral blood of chronic severe hepatitis B patients by Ficoll - Hypaque density gradient centrifugation and cultured with plastic - adherence method. FACS was used to analyze the expression of the CD4 + /CD8 + T cells surface markers, including human leukocyte antigen - DR ( HLA - DR) and CD69. Results At the end of treatment, HBV - DNA levels loss rates were 37% (12 cases) , including HBeAg seroconversion in 5 cases(16% ). In 8 cases(25% ) HBV - DNA levels were decreased and 12 cases ( 37% ) were ineffective. Although interferon alfa - 2b had no effects on the ratio of CD4 + /CD8 + T cells in chronic severe hepatitis B patients, the expression of CD4 + /CD8 + T cells activators, such as CD69 and HLA - DR were upregulated .especially in negative HBV - DNA cases. At 1, 4,12,24 weeks, there was significant difference ( P < 0.05). Compared with the decreased and ineffective cases, CD69/HLA - DR expression rates in negative HBV - DNA cases were the lowest at 24 weeks (P < 0.05 ). Conclusion Interferon alfa - 2b can Up - regulate the expression of CD69/HLA - DR on CD4 + /CD8 + T cells. The activation of CD4 + /CD8 + T cells levels can predict the efficacy in the treatment of HBeAg - positive chronic hepatitis B with interferon alfa - 2b.关键词
干扰素α-2b/肝炎/乙型/慢性/肝炎e抗原/乙型/T淋巴细胞/CD69抗原/HLA-DR抗原Key words
interferon alfa-2b/ hepatitis B, chronic/ hepatitis B e antigens/ T-Lymphocytes/ CD 69/ HLA-DR antigens分类
医药卫生引用本文复制引用
石庆凤,宋吉奎,张颖新,袁建国,王思奎,李庆方,赵红奎..干扰素α-2b治疗HBeAg阳性慢性乙型肝炎患者CD4+/CD8+T细胞活化分子CD69和HLA-DR的表达[J].临床肝胆病杂志,2011,27(12):1285-1287,1300,4.基金项目
2009年聊城市科技局项目 （）
